Literature DB >> 32217657

Urgent need of a management plan for survivors of COVID-19.

Bartolome Celli1, Leonardo M Fabbri2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32217657      PMCID: PMC7098479          DOI: 10.1183/13993003.00764-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
Acute exacerbations of COPD (AECOPD) or “COPD crises” [1], are crucial events in the natural course of COPD. Although they can occur at any severity stage, their impact increases as patients develop more severe airflow limitation. Several studies have demonstrated that the occurrence of COPD exacerbations increases the risk of myocardial infarction and stroke [2], all cause [3, 4] and cardiovascular mortality [5], in the post exacerbation period, particularly in AECOPD with associated pneumonia [6]. This was best demonstrated by Kunisaki et al. in a pre-specified analysis of the data from the SUMMIT trial of over 16 thousand patients with moderate COPD and heightened cardiovascular risk [7]. The authors found that the hazard ratio (HR) for cardiovascular events was increased, particularly in the first 30 days after the exacerbations (HR, 3.8; 95% CI, 2.7–5.5). The risk increased more than twofold if the exacerbations lead to a hospitalisation; where the HR reached 9.9 (95% CI, 6.6–14.9). This study was important because all deaths were analysed by a clinical end-point committee. There was an unusually high number of cardiovascular events occurring after the exacerbations suggesting some vascular dysfunction leading to myocardial infarction, stroke and pulmonary embolism. This scenario appears to be similar to that reported to occur following hospitalised pneumonias, particularly in the elderly [8-10]. The current pandemia of COVID-19 affects primarily adults and particularly those affected by one or more chronic diseases [11]. Because most of the severe COVID-19 are due to pneumonia associated with respiratory failure [11, 12], it is likely that similarly to patients with exacerbations of COPD and/or community acquired pneumonia, the survivors of COVID will be at high risk of cardiovascular events and mortality following the acute phase of the disease. We would like to call attention to this vulnerable period, and recommend that patients be closely followed with a management plan that pays special attention to the prompt recognition of cardiovascular complications, especially in the 30 days following the resolution of the acute phase of the event. It would be a pity that those survivors of COVID-19 pneumonia, would then succumb from a relatively preventable consequence.
  11 in total

1.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

2.  Exacerbations of chronic obstructive pulmonary disease: time to rename.

Authors:  Mona Bafadhel; Gerard Criner; Mark T Dransfield; Wim Janssens; Vanessa M McDonald; Claus F Vogelmeier; Richard Ek Russell; Philip Collis
Journal:  Lancet Respir Med       Date:  2019-11-27       Impact factor: 30.700

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Increased risk of myocardial infarction and stroke following exacerbation of COPD.

Authors:  Gavin C Donaldson; John R Hurst; Christopher J Smith; Richard B Hubbard; Jadwiga A Wedzicha
Journal:  Chest       Date:  2009-12-18       Impact factor: 9.410

5.  Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Authors:  Ken M Kunisaki; Mark T Dransfield; Julie A Anderson; Robert D Brook; Peter M A Calverley; Bartolome R Celli; Courtney Crim; Benjamin F Hartley; Fernando J Martinez; David E Newby; Alexa A Pragman; Jørgen Vestbo; Julie C Yates; Dennis E Niewoehner
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

6.  Incremental risk of long-term mortality with increased burden of comorbidity in hospitalized patients with pneumonia.

Authors:  Mohammed Yousufuddin; Jessica Shultz; Taylor Doyle; Hamid Rehman; Mohammad Hassan Murad
Journal:  Eur J Intern Med       Date:  2018-05-10       Impact factor: 4.487

7.  Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.

Authors:  Catia Cilloniz; Miquel Ferrer; Adamanthia Liapikou; Carolina Garcia-Vidal; Albert Gabarrus; Adrian Ceccato; Jorge Puig de La Bellacasa; Francesco Blasi; Antoni Torres
Journal:  Eur Respir J       Date:  2018-03-29       Impact factor: 16.671

8.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.

Authors:  Chaomin Wu; Xiaoyan Chen; Yanping Cai; Jia'an Xia; Xing Zhou; Sha Xu; Hanping Huang; Li Zhang; Xia Zhou; Chunling Du; Yuye Zhang; Juan Song; Sijiao Wang; Yencheng Chao; Zeyong Yang; Jie Xu; Xin Zhou; Dechang Chen; Weining Xiong; Lei Xu; Feng Zhou; Jinjun Jiang; Chunxue Bai; Junhua Zheng; Yuanlin Song
Journal:  JAMA Intern Med       Date:  2020-07-01       Impact factor: 21.873

9.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

Authors:  Hana Müllerova; Diego J Maselli; Nicholas Locantore; Jørgen Vestbo; John R Hurst; Jadwiga A Wedzicha; Per Bakke; Alvar Agusti; Antonio Anzueto
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

10.  Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia.

Authors:  Beomsu Shin; Sang-Ha Kim; Suk Joong Yong; Won-Yeon Lee; Sunmin Park; Sang Jun Lee; Seok Jeong Lee; Myoung Kyu Lee
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

View more
  3 in total

1.  COPD Management during the COVID-19 pandemic.

Authors:  Sundeep Santosh Salvi; Raja Dhar; P A Mahesh; Zarir Farooq Udwadia; Digambar Behra
Journal:  Lung India       Date:  2021-03

2.  [Recommendations from the German Respiratory Society for Pulmonary Rehabilitation in Patients with COVID-19].

Authors:  R Glöckl; H Buhr-Schinner; A R Koczulla; R Schipmann; K Schultz; M Spielmanns; N Stenzel; S Dewey
Journal:  Pneumologie       Date:  2020-06-24

3.  Predictive Model and Risk Factors for Case Fatality of COVID-19: A Cohort of 21,392 Cases in Hubei, China.

Authors:  Ran Wu; Siqi Ai; Jing Cai; Shiyu Zhang; Zhengmin Min Qian; Yunquan Zhang; Yinglin Wu; Lan Chen; Fei Tian; Huan Li; Mingyan Li; Hualiang Lin
Journal:  Innovation (N Y)       Date:  2020-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.